FOMC minutes; Delta, PepsiCo to report; gold retreats - what’s moving markets
LivaNova PLC stock reached a significant milestone, hitting a 52-week high at 57.52 USD. This marks a notable achievement for the medical technology company, with a 22.2% gain year-to-date and an impressive 36.16% surge over the past six months. According to InvestingPro analysis, the stock currently appears fairly valued, with multiple analysts revising their earnings expectations upward. The stock’s performance indicates strong investor confidence and positive market sentiment, contributing to the upward momentum. With a market capitalization of $3.1 billion and robust gross profit margins of 69.45%, the 52-week high serves as a testament to LivaNova’s strategic initiatives and operational efficiencies. As the company continues to innovate in the healthcare sector, its stock remains a key focus for investors looking for growth opportunities. Discover 12 additional exclusive insights about LivaNova with a subscription to InvestingPro, including detailed financial health scores and comprehensive Pro Research Reports.
In other recent news, LivaNova PLC reported strong second-quarter results for 2025, with earnings per share (EPS) of $1.05, significantly surpassing the expected $0.87. The company also reported revenue of $353 million, exceeding the anticipated $332.21 million. Barclays has responded to these developments by raising its price target for LivaNova to $58 from $55, while maintaining an Equalweight rating. The firm has revised its sales projections upward by approximately 3% for 2025 and 9% on average per year for 2026 and beyond.
Additionally, LivaNova announced the appointment of Donald Zurbay to its Board of Directors and its Audit and Compliance Committee. Zurbay brings extensive experience, having served as President and CEO of Patterson Companies, Inc., and previously as its CFO. His leadership background includes nearly 13 years at St. Jude Medical in various roles, ultimately serving as CFO. These recent developments reflect LivaNova’s strategic moves and financial performance updates.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.